All Stories

  1. The Effectiveness of Transcranial Magnetic Stimulation in Adolescents and Young Adults With Major Depressive Disorder

    Article • JAACAP Open, July 2025, Elsevier

    Scott Aaronson

  2. An examination of symptoms, function and quality of life as conjoint clinical outcome domains for treatment-resistant depression

    Article • Journal of Mood and Anxiety Disorders, June 2025, Elsevier

    Scott Aaronson

  3. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial

    Article • Brain Stimulation, May 2025, Elsevier

    Scott Aaronson

  4. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research

    Article • Psychedelic Medicine, March 2025, Mary Ann Liebert Inc

    Scott Aaronson

  5. Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

    Article • American Journal of Psychiatry, January 2025, American Psychiatric Association

    Scott Aaronson

  6. Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2)

    Article • Journal of Psychiatric Research, August 2024, Elsevier

    Scott Aaronson

  7. The Long Road Toward Equitable MDMA Treatment in the United States

    Article • The Journal of Clinical Psychiatry, May 2024, Physicians Postgraduate Press, Inc

    Scott Aaronson

  8. A Pilot Study of High-Frequency Transcranial Magnetic Stimulation for Bipolar Depression

    Article • The Journal of Clinical Psychiatry, May 2024, Physicians Postgraduate Press, Inc

    Scott Aaronson

  9. Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report

    Article • Brain Stimulation, March 2024, Elsevier

    Scott Aaronson

  10. Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: II. Sensitivity to treatment effects

    Article • Australian & New Zealand Journal of Psychiatry, November 2023, SAGE Publications

    Scott Aaronson

  11. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study

    Article • Neuropsychopharmacology, October 2023, Springer Science + Business Media

    Scott Aaronson

  12. Assessing potential of psilocybin for depressive disorders

    Article • Expert Opinion on Investigational Drugs, October 2023, Taylor & Francis

    Scott Aaronson

  13. Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry

    Article • Brain Stimulation, September 2023, Elsevier

    Scott Aaronson

  14. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician

    Article • Journal of Psychiatric Practice, September 2023, Wolters Kluwer Health

    Scott Aaronson

  15. Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing

    Article • Psychopharmacology, August 2023, Springer Science + Business Media

    Scott Aaronson

  16. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

    Article • Journal of Affective Disorders, April 2023, Elsevier

    Scott Aaronson

  17. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

    Article • Journal of Affective Disorders, April 2023, Elsevier

    Scott Aaronson

  18. The Anxiolytic and Antidepressant Effects of Transcranial Magnetic Stimulation in Patients With Anxious Depression

    Article • The Journal of Clinical Psychiatry, January 2023, Physicians Postgraduate Press, Inc

    Scott Aaronson

  19. Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life

    Article • Psychological Medicine, January 2023, Cambridge University Press

    Scott Aaronson

  20. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2022, New England Journal of Medicine (NEJM/MMS)

    Scott Aaronson

  21. The Emerging Field of Psychedelic Psychotherapy

    Article • Current Psychiatry Reports, September 2022, Springer Science + Business Media

    Scott Aaronson

  22. Optimizing Use of Vagus Nerve Stimulation for the Psychiatric Patient

    Article • Psychiatric Annals, July 2022, SLACK, Inc.

    Scott Aaronson

  23. Vagus Nerve Stimulation and Deep Brain Stimulation: The State of the Art

    Article • Psychiatric Annals, July 2022, SLACK, Inc.

    Scott Aaronson

  24. A narrative review on invasive brain stimulation for treatment-resistant depression

    Article • Brazilian Journal of Psychiatry, June 2022, FRACTAL EDITORA LTDA

    Scott Aaronson

  25. Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry

    Article • Brain Stimulation, March 2022, Elsevier

    Scott Aaronson

  26. Clinical research challenges posed by difficult-to-treat depression

    Article • Psychological Medicine, January 2022, Cambridge University Press

    Scott Aaronson

  27. Systematic review of preservation TMS that includes continuation, maintenance, relapse-prevention, and rescue TMS

    Article • Journal of Affective Disorders, January 2022, Elsevier

    Scott Aaronson

  28. The ‘difficult-to-treat depression’ and the ‘response paradigm’ models: Implications and relevance to patient management

    Article • Australian & New Zealand Journal of Psychiatry, May 2021, SAGE Publications

    Scott Aaronson

  29. Zuranolone in Major Depressive Disorder: Interim Efficacy Results From a Phase 3, Open-Label, Longitudinal Study

    Article • Biological Psychiatry, May 2021, Elsevier

    Scott Aaronson

  30. Zuranolone in Major Depressive Disorder: Interim Safety Results From a Phase 3, Open-Label, Longitudinal Study

    Article • Biological Psychiatry, May 2021, Elsevier

    Scott Aaronson

  31. Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder

    Article • Brain Stimulation, January 2021, Elsevier

    Scott Aaronson

  32. Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation

    Article • Journal of Affective Disorders, December 2020, Elsevier

    Scott Aaronson

  33. A retrospective analysis of bipolar depression treated with transcranial magnetic stimulation

    Article • Brain and Behavior, November 2020, Wiley

    Scott Aaronson

  34. Vagus Nerve Stimulation in Patients Receiving Maintenance Therapy With Electroconvulsive Therapy

    Article • Journal of Ect, October 2020, Wolters Kluwer Health

    Scott Aaronson

  35. 24.3 HIGH-FREQUENCY TRANSCRANIAL MAGNETIC STIMULATION FOR TREATMENT-RESISTANT DEPRESSION IN ADOLESCENTS: THE FIRST MULTICENTER ACTIVE VS SHAM MULTICENTER TRIAL

    Article • Journal of the American Academy of Child & Adolescent Psychiatry, October 2020, Elsevier

    Scott Aaronson

  36. 10.7 HOW MUCH WE KNOW ABOUT ADOLESCENTS WITH TREATMENT-RESISTANT DEPRESSION? DATA FROM A MULTICENTER TRIAL INTERVENTION FOR ADOLESCENT DEPRESSION

    Article • Journal of the American Academy of Child & Adolescent Psychiatry, October 2020, Elsevier

    Scott Aaronson

  37. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial

    Article • Neuropsychopharmacology, September 2020, Springer Science + Business Media

    Scott Aaronson

  38. A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A novel design for a novel treatment

    Article • Contemporary Clinical Trials, August 2020, Elsevier

    Scott Aaronson

  39. The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry

    Article • International Journal of Bipolar Disorders, May 2020, Springer Science + Business Media

    Scott Aaronson

  40. Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance

    Article • Journal of Child and Adolescent Psychopharmacology, May 2020, Mary Ann Liebert Inc

    Scott Aaronson

  41. Neurocognitive effects of transcranial direct current stimulation (tDCS) in unipolar and bipolar depression: Findings from an international randomized controlled trial

    Article • Depression and Anxiety, January 2020, Hindawi Publishing Corporation

    Scott Aaronson

  42. The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF)

    Article • Journal of Psychiatric Research, June 2019, Elsevier

    Scott Aaronson

  43. F30. QUINTUPLE HYPOTHESES TARGETED IN SCHIZOPHRENIA: FIGHT FIRE WITH FIRE

    Article • Schizophrenia Bulletin, April 2019, Oxford University Press (OUP)

    Scott Aaronson

  44. Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression

    Article • February 2019, Dove Medical Press

    Scott Aaronson, Professor Augustus John Rush, Giacomo Mordenti

  45. The Evolving Concept of a Therapeutic Community

    Article • Psychiatry, January 2019, Taylor & Francis

    Scott Aaronson

  46. Neurocognitive Effects of Repetitive Transcranial Magnetic Stimulation With a 2-Coil Device in Treatment-Resistant Major Depressive Disorder

    Article • Journal of Ect, December 2018, Wolters Kluwer Health

    Scott Aaronson

  47. Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial

    Article • Brain Stimulation, November 2018, Elsevier

    Scott Aaronson

  48. Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive

    Article • Australian & New Zealand Journal of Psychiatry, October 2018, SAGE Publications

    Scott Aaronson

  49. Neuromodulation

    Article • Psychiatric Clinics of North America, September 2018, Elsevier

    Scott Aaronson

  50. Vagus Nerve Stimulation

    Article • Psychiatric Clinics of North America, September 2018, Elsevier

    Scott Aaronson

  51. Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression

    Article • The Journal of Clinical Psychiatry, August 2018, Physicians Postgraduate Press, Inc

    Scott Aaronson

  52. T163. Chronic Vagus Nerve Stimulation Significantly and Uniquely Improves Quality of Life in Treatment-Resistant Major Depression

    Article • Biological Psychiatry, May 2018, Elsevier

    Scott Aaronson

  53. Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments

    Article • Schizophrenia Research, March 2018, Elsevier

    Scott Aaronson

  54. The Assessment and Management of Treatment Resistant Depression in the Elderly

    Article • American Journal of Geriatric Psychiatry, March 2018, Elsevier

    Scott Aaronson

  55. International randomized-controlled trial of transcranial Direct Current Stimulation in depression

    Article • Brain Stimulation, January 2018, Elsevier

    Scott Aaronson

  56. Vagus nerve stimulation in patients requiring maintenance therapy after response to electroconvulsive therapy

    Article • European Neuropsychopharmacology, October 2017, Elsevier

    Scott Aaronson

  57. CORRECTION

    Article • American Journal of Psychiatry, September 2017, American Psychiatric Association

    Scott Aaronson

  58. rTMS with a two-coil array: Safety and efficacy for treatment resistant major depressive disorder

    Article • Brain Stimulation, September 2017, Elsevier

    Scott Aaronson

  59. Psychiatric Neurotherapeutics: Contemporary Surgical and Device-Based Treatmentsedited by Joan A. Camprodon, Scott L. Rauch, Benjamin D. Greenberg, and Darin D. Dougherty. New York, Humana Press, 2016, 230 pp., $109.00 (paperback).

    Article • American Journal of Psychiatry, August 2017, American Psychiatric Association

    Scott Aaronson

  60. Efficacy of Vagus Nerve Stimulation in Treatment Resistant Depression

    Article • American Journal of Psychiatry, July 2017, American Psychiatric Association

    Scott Aaronson

  61. 73. Efficacy of Transcranial Direct Current Stimulation in Unipolar and Bipolar Depression: Results from an International Randomized Controlled Trial

    Article • Biological Psychiatry, May 2017, Elsevier

    Scott Aaronson

  62. 418. Five Year Open Label Study of Vagus Nerve Stimulation vs. Treatment as Usual in Severe Treatment Resistant Depression

    Article • Biological Psychiatry, May 2017, Elsevier

    Scott Aaronson

  63. 644. Neurocognitive Effects of Transcranial Direct Current Stimulation (tDCS) in Unipolar and Bipolar Depression: Results from an International Randomized Controlled Trial

    Article • Biological Psychiatry, May 2017, Elsevier

    Scott Aaronson

  64. 641. Neurocognitive Predictors of Antidepressant Efficacy to Transcranial Direct Current Stimulation: Results from an International Randomized Controlled Trial

    Article • Biological Psychiatry, May 2017, Elsevier

    Scott Aaronson

  65. Study design and methodology for a multicentre, randomised controlled trial of transcranial direct current stimulation as a treatment for unipolar and bipolar depression

    Article • Contemporary Clinical Trials, November 2016, Elsevier

    Scott Aaronson

  66. Erratum to “Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study” [Brain Stimulation 9 (2016) 251–257]

    Article • Brain Stimulation, July 2016, Elsevier

    Scott Aaronson

  67. Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study

    Article • Brain Stimulation, March 2016, Elsevier

    Scott Aaronson

  68. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression

    Article • Brain Stimulation, July 2015, Elsevier

    Scott Aaronson

  69. A Randomized Pilot Study of Maintenance NeuroStar Transcranial Magnetic Stimulation (TMS) in Patients with Major Depression

    Article • Brain Stimulation, March 2015, Elsevier

    Scott Aaronson

  70. A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation for Patients With Pharmacoresistant Major Depressive Disorder

    Article • The Journal of Clinical Psychiatry, September 2014, Physicians Postgraduate Press, Inc

    Scott Aaronson

  71. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia

    Article • Schizophrenia Research, August 2014, Elsevier

    Scott Aaronson

  72. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice

    Article • CNS Spectrums, July 2013, Cambridge University Press

    Scott Aaronson

  73. Vagus Nerve Stimulation Therapy Randomized to Different Amounts of Electrical Charge for Treatment-Resistant Depression: Acute and Chronic Effects

    Article • Brain Stimulation, July 2013, Elsevier

    Scott Aaronson

  74. TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICE

    Article • Depression and Anxiety, June 2012, Hindawi Publishing Corporation

    Scott Aaronson

  75. Olanzapine Versus Divalproex Versus Placebo in the Treatment of Mild to Moderate Mania

    Article • The Journal of Clinical Psychiatry, November 2008, Physicians Postgraduate Press, Inc

    Scott Aaronson

  76. Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: Clinical Predictors of Outcome in a Multisite, Randomized Controlled Clinical Trial

    Article • Neuropsychopharmacology, August 2008, Springer Science + Business Media

    Scott Aaronson

  77. Transcranial Magnetic Stimulation in Clinical Psychiatry

    Article • The Journal of Nervous and Mental Disease, March 2008, Wolters Kluwer Health

    Scott Aaronson

  78. P.2.f.002 Olanzapine versus divalproex and placebo for the treatment of mild to moderate mania associated with bipolar I disorder

    Article • European Neuropsychopharmacology, October 2007, Elsevier

    Scott Aaronson

  79. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

    Article • Current Medical Research and Opinion, April 2007, Informa Healthcare

    Scott Aaronson